Principal Scientist
Merck & Co., Inc.
Rahway, New Jersey
Luke Schenck started in pharmaceutical development at Merck in 2001, gaining scale up expertise with conventional granulation and compression processing routes. He later became involved in Merck’s initial hot melt extrusion (HME) development efforts including scale up to achieve Merck’s first PhIII HME delivery. In 2008, he moved to chemical process development and commercialization. Here he worked on the filing the enzymatic transamination route for Januvia and filing Belsomra, Merck’s first HME compound. The primary motivation for the move to drug substance was to explore opportunities at the drug product interface. This initially involved working to identify HME routes to devolatilize API solvates, and additive mediated crystallization efforts as a means to modculate targetted morphology, particle size and form. Since 2015, Luke has been leading the Particle Engineering Lab, identifying routes to manage challenging API properties. The group’s focus includes ‘bottom-up’ generation of nano to micron sized neat API for oral, parenteral, and respiratory delivery routes as well as innovative approaches to deliver co-processed API to address needs of increasingly challenging APIs in development. Since 2018, Luke has been co-leading the IQ Co-Processed API working group.
Disclosure information not submitted.
Monday, October 17, 2022
9:30 AM – 10:30 AM ET
Tuesday, October 18, 2022
8:30 AM – 9:00 AM ET
Tuesday, October 18, 2022
9:00 AM – 11:00 AM ET